Climate versus emission drivers of methane lifetime against loss by tropospheric OH from 1860–2100

With a more-than-doubling in the atmospheric abundance of the potent greenhouse gas methane (CH₄) since preindustrial times, and indications of renewed growth following a leveling off in recent years, questions arise as to future trends and resulting climate and public health impacts from continued growth without mitigation. Changes in atmospheric methane lifetime are determined by factors which regulate the abundance of OH, the primary methane removal mechanism, including changes in CH₄ itself. We investigate the role of emissions of short-lived species and climate in determining the evolution of methane lifetime against loss by tropospheric OH, (τCH₄_OH), in a suite of historical (1860–2005) and future Representative Concentration Pathway (RCP) simulations (2006–2100), conducted with the Geophysical Fluid Dynamics Laboratory (GFDL) fully coupled chemistry-climate model (CM3). From preindustrial to present, CM3 simulates an overall 5% increase in τCH₄_OH due to a doubling of the methane burden which offsets coincident increases in nitrogen oxide (NOx emissions. Over the last two decades, however, the τCH₄_OH declines steadily, coinciding with the most rapid climate warming and observed slow-down in CH₄ growth rates, reflecting a possible negative feedback through the CH₄ sink. Sensitivity simulations with CM3 suggest that the aerosol indirect effect (aerosol-cloud interactions) plays a significant role in cooling the CM3 climate. The projected decline in aerosols under all RCPs contributes to climate warming over the 21st century, which influences the future evolution of OH concentration and τCH₄_OH. Projected changes in τCH₄_OH from 2006 to 2100 range from −13% to +4%. The only projected increase occurs in the most extreme warming case (RCP8.5) due to the near-doubling of the CH₄ abundance, reflecting a positive feedback on the climate system. The largest decrease occurs in the RCP4.5 scenario due to changes in short-lived climate forcing agents which reinforce climate warming and enhance OH. This decrease is more-than-halved in a sensitivity simulation in which only well-mixed greenhouse gas radiative forcing changes along the RCP4.5 scenario (5% vs. 13%)

Decadal changes in summertime reactive oxidized nitrogen and surface ozone over the Southeast United States

Widespread efforts to abate ozone (O3) smog have significantly reduced emissions of nitrogen oxides (NOx) over the past 2 decades in the Southeast US, a place heavily influenced by both anthropogenic and biogenic emissions. How reactive nitrogen speciation responds to the reduction in NOx emissions in this region remains to be elucidated. Here we exploit aircraft measurements from ICARTT (July–August 2004), SENEX (June–July 2013), and SEAC4RS (August–September 2013) and long-term ground measurement networks alongside a global chemistry–climate model to examine decadal changes in summertime reactive oxidized nitrogen (RON) and ozone over the Southeast US. We show that our model can reproduce the mean vertical profiles of major RON species and the total (NOy) in both 2004 and 2013. Among the major RON species, nitric acid (HNO3) is dominant (∼ 42–45%), followed by NOx (31%), total peroxy nitrates (ΣPNs; 14%), and total alkyl nitrates (ΣANs; 9–12%) on a regional scale. We find that most RON species, including NOx, ΣPNs, and HNO3, decline proportionally with decreasing NOx emissions in this region, leading to a similar decline in NOy. This linear response might be in part due to the nearly constant summertime supply of biogenic VOC emissions in this region. Our model captures the observed relative change in RON and surface ozone from 2004 to 2013. Model sensitivity tests indicate that further reductions of NOxemissions will lead to a continued decline in surface ozone and less frequent high-ozone events

Transport of Asian ozone pollution into surface air over the western United States in spring

Many prior studies clearly document episodic Asian pollution in the western U.S. free troposphere. Here, we examine the mechanisms involved in the transport of Asian pollution plumes into western U.S. surface air through an integrated analysis of in situ and satellite measurements in May–June 2010 with a new global high-resolution (∼50 × 50 km2) chemistry-climate model (GFDL AM3). We find that AM3 with full stratosphere-troposphere chemistry nudged to reanalysis winds successfully reproduces observed sharp ozone gradients above California, including the interleaving and mixing of Asian pollution and stratospheric air associated with complex interactions of midlatitude cyclone air streams. Asian pollution descends isentropically behind cold fronts; at ∼800 hPa a maximum enhancement to ozone occurs over the southwestern U.S., including the densely populated Los Angeles Basin. During strong episodes, Asian emissions can contribute 8–15 ppbv ozone in the model on days when observed daily maximum 8-h average ozone (MDA8 O3) exceeds 60 ppbv. We find that in the absence of Asian anthropogenic emissions, 20% of MDA8 O3 exceedances of 60 ppbv in the model would not have occurred in the southwestern USA. For a 75 ppbv threshold, that statistic increases to 53%. Our analysis indicates the potential for Asian emissions to contribute to high-O3 episodes over the high-elevation western USA, with implications for attaining more stringent ozone standards in this region. We further demonstrate a proof-of-concept approach using satellite CO column measurements as a qualitative early warning indicator to forecast Asian ozone pollution events in the western U.S. with lead times of 1–3 days

Phase II Study of a Non-Platinum–Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas

Many patients with lung cancers cannot receive platinum-containing regimens due to co-morbid medical conditions. We designed the PPB regimen of paclitaxel, pemetrexed, and bevacizumab to maintain or improve outcomes while averting the unique toxicities of platinum-based chemotherapies

UBVRI Light Curves of 44 Type Ia Supernovae

We present UBVRI photometry of 44 type-Ia supernovae (SN Ia) observed from 1997 to 2001 as part of a continuing monitoring campaign at the Fred Lawrence Whipple Observatory of the Harvard-Smithsonian Center for Astrophysics. The data set comprises 2190 observations and is the largest homogeneously observed and reduced sample of SN Ia to date, nearly doubling the number of well-observed, nearby SN Ia with published multicolor CCD light curves. The large sample of U-band photometry is a unique addition, with important connections to SN Ia observed at high redshift. The decline rate of SN Ia U-band light curves correlates well with the decline rate in other bands, as does the U-B color at maximum light. However, the U-band peak magnitudes show an increased dispersion relative to other bands even after accounting for extinction and decline rate, amounting to an additional ~40% intrinsic scatter compared to B-band.Comment: 84 authors, 71 pages, 51 tables, 10 figures. Accepted for publication in the Astronomical Journal. Version with high-res figures and electronic data at http://astron.berkeley.edu/~saurabh/cfa2snIa

Protocol for the Smoking, Nicotine and Pregnancy (SNAP) trial: double-blind, placebo-randomised, controlled trial of nicotine replacement therapy in pregnancy

Background: Smoking in pregnancy remains a public health challenge. Nicotine replacement therapy (NRT) is effective for smoking cessation in non-pregnant people, but because women metabolise nicotine and cotinine much faster in pregnancy, it is unclear whether this will be effective for smoking cessation in pregnancy. The NHS Health Technology Assessment Programme (HTA)-funded smoking, nicotine and pregnancy ( SNAP) trial will investigate whether or not nicotine replacement therapy ( NRT) is effective, cost-effective and safe when used for smoking cessation by pregnant women. Methods/Design: Over two years, in 5 trial centres, 1050 pregnant women who are between 12 and 24 weeks pregnant will be randomised as they attend hospital for ante-natal ultrasound scans. Women will receive either nicotine or placebo transdermal patches with behavioural support. The primary outcome measure is biochemically-validated, self-reported, prolonged and total abstinence from smoking between a quit date ( defined before randomisation and set within two weeks of this) and delivery. At six months after childbirth self-reported maternal smoking status will be ascertained and two years after childbirth, self-reported maternal smoking status and the behaviour, cognitive development and respiratory symptoms of children born in the trial will be compared in both groups. Discussion: This trial is designed to ascertain whether or not standard doses of NRT ( as transdermal patches) are effective and safe when used for smoking cessation during pregnancy

Could MicroRNAs be Useful Tools to Improve the Diagnosis and Treatment of Rare Gynecological Cancers? A Brief Overview

Gynecological cancers pose an important public health issue, with a high incidence among women of all ages. Gynecological cancers such as malignant germ-cell tumors, sex-cord-stromal tumors, uterine sarcomas and carcinosarcomas, gestational trophoblastic neoplasia, vulvar carcinoma and melanoma of the female genital tract, are defined as rare with an annual incidence of <6 per 100,000 women. Rare gynecological cancers (RGCs) are associated with poor prognosis, and given the low incidence of each entity, there is the risk of delayed diagnosis due to clinical inexperience and limited therapeutic options. There has been a growing interest in the field of microRNAs (miRNAs), a class of small non-coding RNAs of 22 nucleotides in length, because of their potential to regulate diverse biological processes. miRNAs usually induce mRNA degradation and translational repression by interacting with the 30 untranslated region (30-UTR) of target mRNAs, as well as other regions and gene promoters, as well as activating translation or regulating transcription under certain conditions. Recent research has revealed the enormous promise of miRNAs for improving the diagnosis, therapy and prognosis of all major gynecological cancers. However, to date, only a few studies have been performed on RGCs. In this review, we summarize the data currently available regarding RGCs.peer-reviewe